<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-62900</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:description xml:lang="en">Efalizumab (Raptiva®) is one of the biological agents approved recently for the treatment of patients with moderate-severe psoriasis who have not responded to conventional treatments. It is a humanized IgG1monoclonal antibody which, due to its anti-D11 effect, is capable of blocking the endothelial migration and Tcell activation on the skin, fundamental processes in the etiopathogeny of psoriasis. We present the experience we have had in our hospital over the last two years with 23 patients who have initiated treatment with efalizumab (AU)</dc:description>
<dc:creator>González Hermosa, MR</dc:creator>
<dc:creator>Díaz-Pérez, JL</dc:creator>
<dc:creator>Martínez de Lagrán, Z</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Efalizumab (Raptiva®) es uno de los agentes biológicos aprobados recientemente para el tratamiento de pacientes con psoriasis de intensidad moderada-grave que no hayan respondido a tratamientos convencionales. Es un anticuerpo monoclonal humanizado que por su efecto anti-CD11 es capaz de bloquear la migración endotelial y la activación de los linfocitos T a nivel cutáneo, procesos fundamentales en la etiopatogenia de la psoriasis. Presentamos la experiencia que a lo largo de los dos últimos años hemos tenido en nuestro hospital con los 23 pacientes que han iniciado tratamiento con efalizumab (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;99(supl.1): 74-81, ene. 2008. ilus, tab</dc:source>
<dc:identifier>ibc-62900</dc:identifier>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d8657^s22045</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23473^s22053</dc:subject>
<dc:subject>^d23473^s22021</dc:subject>
<dc:subject>^d12002^s22027</dc:subject>
<dc:subject>^d12002^s22057</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d920^s22038</dc:subject>
<dc:subject>^d12002^s22053</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d920^s22079</dc:subject>
<dc:subject>^d920^s22078</dc:subject>
<dc:subject>^d12002^s22080</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:type>article</dc:type>
<dc:date>200801</dc:date>
</metadata>
</record>
</ibecs-document>
